Clinical Trials

Manhattan Hematology Oncology Associates

AML-FLT3

Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.

The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

Mantle Cell Lymphoma

Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

Leukemia and Lymphomas CLL/SLL and MCL

Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) or Mantle cell lymphoma (MCL) Oncternal Study

Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies.

This research study will evaluate an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), for treatment of patients with CLL/SLL or MCL.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

B-Cell Lymphoma Beigene Study

Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib

Now enrolling patients for a phase 2 clinical study for the treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, and Marginal Zone Lymphoma with Zanubrutinib (BGB-3111)

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

Colon Cancer CRC Trial

Now Enrolling Patients for an Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

Myelofibrosis Abbvie Study

Now Enrolling Patients for a Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

CLL/SLL Non-Hodgkin's Lymphoma

Now enrolling patients in A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas

CG-806 is a small molecule kinase inhibitor with the potential to treat patients with broad range of B cell malignancies, including those that are sensitive to and those resistant, refractory, or intolerant to standard therapies, as well as a breadth of patients with AML, including those resistant to current FLT3 inhibitors.

CG-806 is the first agent to potentially inhibit all known forms of both FLT3 and BTK enzymes and to inhibit key oncogenic compensatory pathways without inhibiting kinase generally known to induce toxicity.

Purpose of the study:

  • To determine the dose of CG-806 given orally every 12 hours that maintains a biologically active plasma concentration over a period of 28 days.
  • To establish the recommended Phase 2 dose (RP2D) of CG-806 for future clinical trials in patients with advanced CLL/SLL or NHL.
  • To determine the PK profile of CG-806 when administered orally on an every 12 hour schedule.
  • To assess the antitumor activity of CG-806 using imaging and biomarker evaluations.
  • To determine the ability of CG-806 to alter the expression of pharmacodynamic biomarkers of drug effect.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinator

212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com

Meet Our Doctors

Alec Goldenberg, M.D.

Dr. Goldenberg, Founding Physician of Manhattan Hematology Oncology Associates (MHOA), graduated Magna Cum Laude from Brandeis University with High Honors in Mathematics, before receiving his MD from The Johns Hopkins University School of Medicine in 1980. He completed his internship and residency at Bellevue-New York University Hospitals, where he was also Chief Resident. Dr. Goldenberg continued his training as a fellow at Memorial Sloan Kettering in New York City before becoming the Director of the Hematology Clinic at the NYU Medical Center. Board certified in Internal Medicine and Medical Oncology, Dr. Goldenberg is currently a Clinical Associate Professor of Medicine at the New York University School of Medicine, and an Attending Physician at New York University Medical Center.


READ MORE

dr-g-mhony

Karen Haglof, M.D.

Dr. Karen Haglof, Associate Physician at Manhattan Hematology Oncology Associates (MHOA), graduated Summa Cum Laude from City University of New York, Hunter College before receiving her MD with Magna Cum Laude distinction from State University of New York. Completing her internship and residency in Internal Medicine at the University of Florida in Gainesville, Florida, Dr. Haglof continued her post-graduate medical training as a Hematology/Oncology Fellow at New York University in New York City. Dr. Haglof continued her strong relationship with NYU and Bellevue Hospitals, where she is currently an Attending Physician and Clinical Instructor in Hematology and Oncology.


READ MORE

dr-h-mhony

To schedule an appointment
or to get more information about
Manhattan Hematology Oncology Associates:

 

    Patient Reviews

    • Laura Zente
      I was terrified to have the bone marrow biopsy procedure, but thanks to the special needle that Dr. Goldenberg invented, and his incredibly experienced nurse Priscilla, it was less painful than going to the dentist!
      Laura Zente
    • Kara A
      You are not just a medical chart to Dr. Goldenberg; you are a real person with real concerns. And now, 18 months later, I am celebrating One Year Cancer Free!
      Kara A
      Stage IV Colon Cancer
    • Peri I.
      What I realized by having the good fortune to find Dr. Goldenberg, is that the scary things on the internet about having a bone marrow biopsy are not true.
      Peri I.
      Essential Thombocythemia
    • Veronica Miller
      My time with Dr. Goldenberg has made me realize how strong a person I am. I put my life in his talented care, and in order to survive I learned to overcome my fear and look for the positive. Now that I am healthy, I share with my own patients the encouragement that he gave to me to get up and walk, and to make movement one of the keys to reclaiming health.
      Veronica Miller
      Multiple Myeloma
    • Ed from Yonkers
      If not for Dr. Karen Haglof, I may not be doing so well right now. I am a very lucky person.
      Ed from Yonkers
      CLL
    • Dr. Marc Kantrowitz
      It is New York and there are plenty of good doctors. The trick is to find one who is an excellent doctor and a good person, and Dr. Goldenberg was that fit for me.
      Dr. Marc Kantrowitz
      Deep Vein Thrombosis (DVT)
    • Vincent Love
      I tend to be very cautious-in fact, I tend to see more of the “hole in the doughnut” while Dr. Haglof sees the whole thing. It’s comforting that she is optimistic and positive, and I like her a lot. I feel good again, and things are going in the right direction. So far so good..and I am in very competent hands!
      Vincent Love
      CLL
    • Laura Murray
      One of the best calls I made this year was to Dr. Goldenberg, on the one year anniversary of the date of my diagnosis. Out of the woods medically, thanks to an unrelated donor in Germany, I've now in a new role as a cancer patient advocate to increase awareness for the need of participation in the bone marrow registry. Thanks to Dr. Goldenberg's uniquely compassionate care, I am able to experience this past year as a gift in disguise.
      Laura Murray
      Hodgkin’s Lymphoma
    • Geoffrey Rogow
      Dr. Haglof is one of my favorite people on the planet and I would tell everyone about her. I am back to work and in remission. I can’t possibly repay her, but if I could find a way to repay Dr. Haglof, well..I’d never do anything else with my life!
      Geoffrey Rogow
      Primary mediastinal B-cell lymphoma
    • Sophia S.
      Dr. Goldenberg and his first-rate staff at Manhattan Hematology Oncology Associates have brilliantly and compassionately helped me navigate the trail to recovery.
      Sophia S.
      Acute Myeloid Leukemia
    • Shelley Blye
      I often think of how lucky I was to have chosen a physician that I was able to trust 100% as my advocate.
      Shelley Blye
      Liver Cancer
    • Irma Gotay
      The Cancer had me and Dr. Goldenberg to contend with. I never felt like a cancer patient, Dr. Goldenberg’s office felt like another home to me.
      Irma Gotay
      Stage III Breast Cancer
    • Barbara Lande
      My time with Dr. Goldenberg has made me realize how strong a person I am. I put my life in his talented care, and in order to survive I learned to overcome my fear and look for the positive. Now that I am healthy, I share with my own patients the encouragement that he gave to me to get up and walk, and to make movement one of the keys to reclaiming health. I would never go anywhere else!
      Barbara Lande
      Follicular Lymphoma
    • Eric H. Weinberger
      Dr. Haglof is a rare human being- funny, dedicated, and incredibly competent.
      Eric H. Weinberger
      Stage IV Lung Cancer
    • Victor Ledezma
      Dr. Haglof made the frightening process of surviving cancer easier by providing a sense of positivity throughout the course of my care.
      Victor Ledezma
      Stage 4 Hodgkin Lymphoma
    • Gregg Gordon & Caryn Gordon
      Dr. Goldenberg’s dedication extends to both his patients and to their families. When my husband Gregg was sick, Dr. Goldenberg took the time to encourage and endorse a book that our daughter Ali wrote to help other AML family members. Our family believes this kind of patient support from an oncologist is rare.
      Gregg Gordon & Caryn Gordon
      Acute Myeloid Leukemia
    • Carla Santini
      Dr. Goldenberg’s love for his work is unmatched and his medical expertise and overall core values related to patient management shine through every time.
      Carla Santini
      Breast Cancer